Literature DB >> 10945504

Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid.

P Hinnen1, F W de Rooij, E M Terlouw, A Edixhoven, H van Dekken, R van Hillegersberg, H W Tilanus, J H Wilson, P D Siersema.   

Abstract

5-Aminolaevulinic acid (ALA)-induced porphyrin biosynthesis, which is used for ALA-based photodynamic therapy (ALA-PDT), was studied in tissues of 10 patients with Barrett's oesophagus (BE) and adenocarcinoma of the oesophagus (AC) undergoing oesophagectomy at a mean time interval of 6.7 h after the ingestion of ALA (60 mg kg(-1)). In BE, AC, squamous epithelium (SQ) and gastric cardia, the activities of the haem biosynthetic enzymes porphobilinogen deaminase (PBG-D) and ferrochelatase (FC) and the PDT power index--the ratio between PBG-D and FC in BE and AC in comparison with SQ--were determined before ALA ingestion. Following ALA administration, ALA, porphobilinogen, uroporphyrin I and PPIX were determined in tissues and plasma. The PDT power index did not predict the level of intracellular accumulation of PPIX found at 6.7 h. In BE, there was no selectivity of PPIX accumulation compared to SQ, whereas in half of patients with AC selectivity was found. Higher haem biosynthetic enzyme activities (i.e. PBG-D) and lower PPIX precursor concentrations were found in BE and AC compared to SQ. It is therefore possible that PPIX levels will peak at earlier time intervals in BE and AC compared to SQ.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945504      PMCID: PMC2374652          DOI: 10.1054/bjoc.2000.1300

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  M J Edwards; D R Gable; A B Lentsch; J D Richardson
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

2.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

Authors:  D J Drewitz; R E Sampliner; H S Garewal
Journal:  Am J Gastroenterol       Date:  1997-02       Impact factor: 10.864

3.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus.

Authors:  A van der Burgh; J Dees; W C Hop; M van Blankenstein
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

4.  Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid.

Authors:  L Gossner; M Stolte; R Sroka; K Rick; A May; E G Hahn; C Ell
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

5.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.

Authors:  A J Cameron; H A Carpenter
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

Review 6.  Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment.

Authors:  G W Clark; A P Ireland; T R DeMeester
Journal:  Dig Dis       Date:  1996 Jul-Aug       Impact factor: 2.404

7.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

8.  5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration.

Authors:  J van den Boogert; R van Hillegersberg; F W de Rooij; R W de Bruin; A Edixhoven-Bosdijk; A B Houtsmuller; P D Siersema; J H Wilson; H W Tilanus
Journal:  J Photochem Photobiol B       Date:  1998-06-15       Impact factor: 6.252

9.  Hemodynamic effects of 5-aminolevulinic acid in humans.

Authors:  M A Herman; J Webber; D Fromm; D Kessel
Journal:  J Photochem Photobiol B       Date:  1998-04       Impact factor: 6.252

10.  Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus.

Authors:  P Hinnen; F W de Rooij; M L van Velthuysen; A Edixhoven; R van Hillegersberg; H W Tilanus; J H Wilson; P D Siersema
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more
  9 in total

1.  Oligopeptide Transporter-1 is Associated with Fluorescence Intensity of 5-Aminolevulinic Acid-Based Photodynamic Diagnosis in Pancreatic Cancer Cells.

Authors:  Hidehito Kinoshita; Tsutomu Kanda; Tomoaki Takata; Takaaki Sugihara; Yukari Mae; Taro Yamashita; Takumi Onoyama; Yohei Takeda; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2020-06-12       Impact factor: 1.641

2.  5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial.

Authors:  M Hage; P D Siersema; H van Dekken; E W Steyerberg; J Haringsma; W van de Vrie; T E Grool; R L P van Veen; H J C M Sterenborg; E J Kuipers
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  The proton-coupled oligopeptide transporter 1 plays a major role in the intestinal permeability and absorption of 5-aminolevulinic acid.

Authors:  Yehua Xie; Yongjun Hu; David E Smith
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

4.  Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation?

Authors:  L Greenbaum; Y Gozlan; D Schwartz; D J Katcoff; Z Malik
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

Review 5.  Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement.

Authors:  Xue Yang; Pratheeba Palasuberniam; Daniel Kraus; Bin Chen
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

6.  Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid.

Authors:  Izumi Kirino; Katsuhiko Fujita; Kei Sakanoue; Rin Sugita; Kento Yamagishi; Shinji Takeoka; Toshinori Fujie; Shinji Uemoto; Yuji Morimoto
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

7.  Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study.

Authors:  Hideo Fukuhara; Takahiro Nohara; Koshiro Nishimoto; Yutaka Hatakeyama; Yuki Hyodo; Yoshiyasu Okuhara; Masafumi Oyama; Atsushi Mizokami; Keiji Inoue; Hideyasu Matsuyama
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

Review 8.  Fluorescent contrast agents for tumor surgery.

Authors:  Qi Xiao; Tianming Chen; Shilin Chen
Journal:  Exp Ther Med       Date:  2018-07-04       Impact factor: 2.447

Review 9.  Analysis of Factors Affecting 5-ALA Fluorescence Intensity in Visualizing Glial Tumor Cells-Literature Review.

Authors:  Marek Mazurek; Dariusz Szczepanek; Anna Orzyłowska; Radosław Rola
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.